Shedding of tumor necrosis factor receptors by activated human neutrophils by unknown
Shedding of Tumor Necrosis Factor Receptors by
Activated Human Neutrophils
By Franyoise Porteu and Carl Nathan
Summary
The capacity of human neutrophils (PMN) to bind tumor necrosis factor (TNF) was rapidly
lost when the cells were incubated in suspension with agents that can stimulate their migratory
and secretory responses. Both physiological (poly)peptides (FMLP, C5a, CSF-GM) and phar-
macologic agonists (PMN, calcium ionophore A23187) induced the loss ofTNF receptors (TNF-R)
from the cell surface. Half-maximal loss in TNF-R ensued after only ti2 min with 10 -7 M
FMLP at 37°C, and required only 10-9 M FMLP during a 30-min exposure. However, there
were no such changes even with prolonged exposure of PMN to FMLP at 4° or 16°C. Scatchard
analysis revealed loss of TNF-binding sites without change in their affinity (Kd -0.4 nM) as
measured at incompletely modulating concentrations of FMLP, C5a, PMA, or A23187. The
binding of anti TNF-R mAbs to PMN decreased in parallel, providing independent evidence
for the loss of TNF-R from the cell surface. At the same time, soluble TNF-R appeared in the
medium of stimulated PMN. This inference was based on the PMN- and FMLP-dependent
generation of a nonsedimentable activity that could inhibit the binding of TNF to fresh human
PMN or to mouse macrophages, and the ability of mAbs specific for human TNF-R to abolish
inhibition by PMN-conditioned medium of binding of TNF to mouse macrophages. Soluble
TNF-R activity was associated with a protein of Mr -28,000 by ligand blot analysis of cell-free
supernatants of FMLP-treated PMN. Thus, some portion of the FMLP-induced loss of TNF-R
from human PMN is due to shedding of TNF-R. Shedding was unaffectedby inhibitors of serine
and thiol proteases and could not be induced with phosphatidylinositol-specific phospholipase
C. Loss of TNF-R from PMN first stimulated by other agents may decrease their responsiveness
to TNF. TNF-R shed by PMN may be one source of the TNF-binding proteins found in body
fluids, and may blunt the actions of the cytokine on other cells.
unng infection (1), allograft rejection (2), and ischemic
tissue damage (3), macrophages and lymphocytes pro-
duce TNF-ci, a pro-inflammatory cytokine (4) with profound
effects on neutrophils (PMN).' In rats injected with TNF
intravenously, PMN invade the walls ofblood vessels in organs
undergoing hemorrhagic necrosis (5). In mice injected with
TNF intradermally, the skin undergoes hemorrhagic necrosis
only in animals that can generate or are repleted with the
PMN chemoattractant C5a (6), and only if they can mobi-
lize a radiosensitive populationof non-T cells (7); PMN mass
within and aroundblood vessels supplying the areas destined
for infarction (6, 7) . In vitro, TNF enhances the expression
of CD11b/CD18 adhesion molecules on PMN (8), increases
PMN adhesion to endothelium (8), triggers adherent (9) PMN
'Abbreviations used in this paper. CSF-GM, CSF for granulocyte/ma-
crophage; DFP, diisopropylfluorophosphate; KRPG, Krebs-Ringer
phosphate buffer with glucose; PMN, neutrophils; TGF-01, trans-
forming growth factor-,Q1.
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that express CD11/CD18 (10) to release large amounts ofreac-
tive oxygen intermediates, and promotes PMN degranula-
tion (11), phagocytosis (11, 12), and antibody-dependent cy-
totoxicity (12).
We set out to identify physiologic mechanisms that may
counteract the potentially destructive stimulation of PMN
by TNF (13, 14). One such mechanism couldinvolve regula-
tion of cell surface receptors for TNF (TNF-R). A single
class of TNF-R with a Kd of 0.1-1 nM has been identified
on PMN by ligand binding (15-17). On cells other than PMN,
cross-linking experiments have demonstrated association of
TNF with a variety of proteins ranging from 50 to 140 kD
(reviewed in reference 18). mAbs that mimic biologic effects
of TNF while inhibiting the ability of cells to bind TNF
are thought to be directed against TNF-R (19) . These mAbs
react with cellular proteins of -55 and 75 kD (20), but their
binding to PMN has not been documented. On some cells,
the number of TNF-R can be increased by treatment with
IFN-.y (21), IL-2 (22), or agents that elevate CAMP (23), or
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protein kinase C (23, 26, 27), inhibitors of protein synthesis
(28), and drugs that depolymerize (28) or stabilize (29)
microtubules. However, binding of TNFdidnot change after
treatment of PMN with LPS (25), cycloheximide (28), or
microtubule-disrupting agents (28), and effects of the other
regulators on TNF-Rof PMNhave notbeen described. Thus,
there hasbeen no evidence that theTNF-R of PMN are sub-
ject to regulation.
We demonstratebelow that exposure of PMN to a variety
of physiologic andpharmacologic stimuliresults in rapidloss
of TNF-R from the cell surface. Medium conditioned by
stimulated PMN contained soluble molecules that bound TNF
and reacted with mAbs to TNF-R. Thus, activated PMN
shed TNF-R. Shedding of TNF-R by activated PMN may
both blunt their responsiveness to TNF, and diminish the
concentration of TNF able to act on other cells.
Materials and Methods
Cells.
￿
PMN were isolated from heparinized blood of healthy
adults by centrifugation on Neutrophil Isolation Medium (Los
Alamos Diagnostics, Los Alamos, NM) as described (9). Con-
taminating erythrocytes were lysedwith 0.2% NaCl for90 s. PMN
were washed and resuspended at 5 x 106/ml in ice-cold Krebs-
Ringer phosphate buffer with glucose, pH 7.2-7.4, 300 mosM
(KRPG) containing 0.2% heat-inactivated FCS (HyClone Labora-
tories, Logan, UT). PMN were incubatedin 1.5-mlpolypropylene
microfuge tubes(Brinkmann Instruments Co., Westbury, NY) at
37°C with chemotactic factors, cytokines, or medium alone, while
rotating end-over-end for timesvaryingfrom 1 to 90 min. For in-
cubations of <10min, thecellswere prewarmed for 10 min at 37°C
before addition of the stimulus. After incubation, the cells were
washed with cold KRPG,resuspended in bindingbuffer, andtested
for TNF-R as described below.
Peritoneal exudates were elicited in CD1 mice (Charles River
Breeding Laboratories, Wilmington, MA) with thioglycolatebroth
(Difco Laboratories, Detroit, MI) and thecells harvestedas described
(25).Monolayers of adherent macrophages were obtained by plating
1 x 106 cells/well in 16-mm-diameter wellsin plastic trays (Costar
Data Packaging, Cambridge, MA) in a-modified MEM (ceMEM;
KC Biological, Lenexa, KS) with 10% FCS. Macrophages were
maintained at 37°C in 5% CO2/95% air for 1-4 d before ex-
periments.
Stimuli and Other Reagents.
￿
All cytokines were pure, recom-
binant proteins of human origin. TNF (5.6 x 10' U/mg) pro-
duced in Escherichia coli was a gift of Genentech (South San Fran-
cisco, CA). IFN-y (1 x 10' U/ml) and transforming growth
factor-(31 (TGF-01, 50 hg/ml) were gifts of Amgen (Thousand
Oaks, CA). CSF for granulocyte/macrophage (CSF-GM, 1.4 x
10' U/ml; from Chinese hamster ovary cells) was from Genetics
Institute (Cambridge, MA). IL1-/3 was a gift of Dr. C. Dinarello
(Tufts New England Medical Center, Boston, MA). Pure, recom-
binant human C5a wasprovided by Dr. HenryShowell, Pfizer Inc.
(Groton, CT).
FMLP, PMA, and the calcium ionophore A23187 were from
Sigma Chemical Co. (St. Louis, MO). Stock solutions of FMLP
(10-' M) and A23187 (10-2 M) in DMSO were stored at -70°C.
Protease inhibitors were from Sigma Chemical Co. Phosphatidy-
linositol-specific phospholipase Cfrom Bacillus thuringiensis was from
Dr. M.G. Low (Columbia University College of Physicians and
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Surgeons, NewYork, NY), and wasagift of Dr. A. LeBivic, Cor-
nell University Medical College.
Antibodies.
￿
Purified mouseIgG1 mAbs Htr-5, Htr-9, and Utr-1
specific for human TNF-R, prepared as described (20), were the
gift of Dr. ManfredBrockhaus, F. Hoffman-La Roche AG, Basel,
Switzerland. Purified mouse IgG2a mAbs 1134 (anti-CD18) and
W6/32 (anti-HLAA, $ C) were gifts ofDr. S. Wright, TheRocke-
feller University, NewYork, NY Purified mouseIgM mAb BH2C6
anti-p157 (not CD11) (30) was the gift of Dr. J. Michl, SUNY,
Brooklyn, NY Affinity purified F(ab')2 fragments of goat IgG
anti-mouse IgG were from Cappel Laboratories (Organon Teknika
Corp., West Chester, PA).
Iodination ofCytokinesandAntibodies.
￿
TNF andaffinity-purified
F(ab')2 fragments of anti-mouse IgG were radiolabeled with 1251
according to the method of Aggarwal et al. (21) using Iodogen-
coated tubes and0.5-1 mCi of Na1a'I (100 mCi/ml; Radiochem-
ical Center, Amersham). As before (25, 28, 29), 1251TNFa had
a specific activity of 200-400 Ci/mmol monomer, migrated as a
single band of 17 kD on 11% polyacrylamide gels, and retained
fully its ability to enhance H202 releasing capacity of resident
mouse peritoneal macrophages. Radiolabeling of rhuIFN-y was
performed as described (31) .
Binding Assays.
￿
Replicate samples of 1 x 106 PMN in 0.3 ml
of KRPG containing 5% FCS (binding buffer) were incubated with
the indicated concentrations of 1251TNF (0.1-2 nM) or 1251-IFN-y
(2 nM) in the presence or absence of a 100-fold molar excess of
unlabeled ligand to determine nonspecific binding. After 3 h at
4°C (sufficient to reachequilibrium), the cellswere washed three
times with 0.9% NaCl by centrifugation (180 g, 10 min, 4°C)
andsolubilized with 30 p.l of 1 N NaOH. The lysates were trans-
ferred into new tubes for gamma counting (Packard Instrument
Co., DownersGrove, IL). Nonspecific bindingwas <15% of total
binding and was subtracted. Protein concentration of the solubi-
lized samples was determined by the assay of Lowry et al. (32).
Results are expressed as specific cpm bound per 100 lAg protein.
Binding of 12'ITNF-a to monolayers of adherent macrophages was
measured as described (25, 28, 29).
For binding of mAbs, PMN (1 x 106 in 100 pl of KRPG with
10% FCS) were incubatedwith saturating amounts of mAbs (10-20
pg/ml) for 1 h at 4°C, washed twice in KRPG-10% FCS, and
reacted for an additional 30 min at 4°C with 1251-F(ab')2 anti-
mouse IgG (500,000 cpm). After three washes in saline (180 g,
4°C, 10 min), bound cpm and protein were measured as above.
Background bindingwasdetermined by omitting the primaryan-
tibody and was subtracted. It varied from 2 to 5% of totalbinding
for anti-HLA and anti-CD18 mAbs, to -30% for mAbs
antiTNF-R.
AssayforSoluble TNF-R.
￿
TNF-Rwere detected in the condi-
tioned medium of stimulated PMN by competition with 1251-TNF
for its binding to fresh PMN or macrophages. PMN (1.0-1.2 x
108/ml) were incubated in KRPG-I% FCS for 10 min at 37°C
with FMLP (10-1 M) or medium alone. The supernatants were
harvestedby centrifugation (180g, 10 min, 4°C), centrifuged again
(12,000 g, 5 min, 4°C), and incubated with 2 nM 1251-TNF in the
presence or absence of 200 nM unlabeled TNF and/or a mixture
of theanti-human TNF-RmAbs Htr-5, Htr-9, andUtr-1(5 hg/ml
each). After 30 minat 4°C, themixtures were transferred to wells
containing monolayers of macrophages or 1 x 106 fresh PMN,
and binding was allowed to proceed for 3 h at 4°C as described
above. As a control, 10-6 M FMLP was added to supernatants
from buffer-treated cells during the binding assay.
GelElectrophoresisandLigand Blot Analysis.
￿
Cell-free superna-
tants of PMN treated with buffer aloneor stimulated with FMLPwere resolved by electrophoresis in 5-15% polyacrylamide gradient
gels according to the procedure ofLaemmli (33) under nonreducing
conditions. The proteins were then transferred to nitrocellulose
membranes (Schleicher & Schnell Inc., Keene, NH) at 100 V for
1 h at room temperature, using the buffer systems described by
Burnette (34). The nitrocellulose sheets were blocked with 1%
nonfat dry milk in 50 mM Tris-HCI pH 7.4,140 mM NaCl, 5 mM
EDTA and 1 mM sodium azidefor 2 h at room temperature before
addition of 1251TNF (0.5 nM) in the presence or absence of 100
nM unlabeled TNF. After 16 h at 4°C, the membranes were washed
four times with PBS at room temperature, dried, and autoradio-
graphed.
Measurement ofLPS.
￿
The level ofcontaminatingLPS in all media
and reagents was monitored by a chromogenic limulus amebocyte
lysate test (Whittaker Bioproducts, Inc., Walkerville, MD) with
a sensitivity of 10 pg/ml.
Results
E$ects ofPMNActivators on Expression ofTNFR.
￿
Exposure
of PMN for 45 min at 37°C to FMLP (10 -e to 10-7 M),
PMA (100 ng/ml), or calcium ionophore A23187 (10 -5 M)
resulted in almost complete inhibition of the subsequent
binding of 1251-TNF at 4°C (Table 1). Exposure of PMN to
C5a (10-1 M) or CSF-GM (100 ng/ml) also suppressed their
subsequent binding of TNF. However, in contrast to the effect
Table 1.
￿
Elects of Various PMN Activators on the Ability
of PMN to Bind TNF
Treatment"
FMLP
rC5a
A23187
PMA
rCSF-GM
rIFN-,y
rTGF-/31
rIL-1(3
LPS
1211-TNF binding
(percent of untreated control)t
after treatment at 37°C for;
10 min
￿
45 min
" PMN were incubated for 10 or 45 min at 37°C with the indicated
reagent, washed and assayed for 1251-TNF binding at 4°C as
described.
t TNFcr-specific binding is given as a percent of specific binding
seen with cells treated for 10 or 45 min at 37°C with buffer alone;
the latter value averaged 5,525 ± 1,256 cpm/100 leg protein.
Results are means ± SD from the number of independent experi-
ments indicated in parentheses.
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observed with FMLP, PMA, or A23187, the decrease in
1251-
TNF binding induced by C5a or CSF-GM was never com-
plete; 30-50% specific binding remained even when the in-
cubation time was prolonged to 2 h at 37°C (not shown).
In contrast, IFN-y, ILla, and TGF-(31 (each 100 ng/ml)
had little or no effect on TNF-R expression (Table 1). A 45-
min exposure to high concentrations of LPS (0.1-1 hg/ml)
reduced 1251-TNF binding only slightly (20-30%), and a 10-
min exposure to LPS had no detectable effect (Table 1). The
measured LPS content of all reagents at the concentrations
used was <10 pg/ml. Thus, downregulation of TNF-R in-
duced by other agents couldnot be attributed to contamina-
tion by LPS.
Kinetic Studies of TNF-R Modulation.
￿
The decrease in
binding of 125ITNF induced by FMLP was extremely rapid,
50% reduction being reached after N3 min treatment with
10-8M FMLP (Fig. 1). Complete loss of 1251TNF binding
required 6-10 min exposure to 10-1 M FMLP or 12-15 min
exposure to 10 -8 M FMLP (Fig. 1) . Likewise, binding of
125ITNF to PMN was decreased to 0-5% that of control
cells by 10 min after addition ofPMA or A23187, and 30-70%
binding capacity of the cells was lost upon a 10-min incuba-
tion with C5a and CSF-GM (Table 1).
The decrease in TNF binding induced by FMLP was rela-
tively long lasting. After PMN were exposed to FMLP for
15 min and washed, their capacity to bind TNF recovered
only partially during a subsequent 2-h incubation at 37°C
(Table 2). Recovery studies were not carried out to longer
times because prolonged incubation was associated with a
fall in TNF-R on control PMN (data not shown) .
TemperatureDependence.
￿
In contrast to the results obtained
at 37°C, pre-exposure of PMN for 30 min at 4°C to FMLP,
C5a, CSF-GM, A23187, or PMA, or addition of these factors
during the binding assay, did not affect TNF binding. Nei-
ther FMLP nor C5a induced a decrease in TNF binding when
Incubation time (min)
Figure 1.
￿
Time course of FMLP-induced downregulation of TNF
binding capacity. PMN were incubated at 37°C for the indicated
times with either 10-7 M FMLP ("), 10 -e M FMLP (A), or buffer
alone (O) before binding of 1251-TNF was measured at 4°C. The
results are means ± SE of triplicates. When error bars are not seen,
they fall within the symbols.
10-7 M 13 ±5 (4) 9±4(4)
10-1 M 17 ±4 (4) 12 ±9 (2)
10-7 M 41 ± 14 (4) 34 t 3 (2) M
10 -1 M 58 ± 2 (3) 55 ± 2 (2)
I
0
10 -1 M 4 ± 1 (2) 1 ± 1 (2) x
100 ng/ml 0 ± 0 (3) 0 ± 0 (3)
100 ng/ml 67 ± 1 (2) 50 ± 18 (2)
0 v
100 ng/ml 95 93 ± 1 (2) E
U
100 ng/ml 100 90 ± 4 (2) o.
100 ng/ml ND 91 'v
1 wg/ml 104 ± 20 (3) 73 ± 6 (3)
100 ng/ml 104 ± 12 (3) 82 ± 7 (3)
U
k
U
d aTable 2.
￿
Partial Recovery of TNF-R after Downregulation
by FMLP
TNF binding (percent of control)t
' PMN were pulsed with either buffer alone or 10 -7 M FMLP for
15 min at 37°C, washed three times, and incubated in fresh medium
at 37°C for the indicated times before the TNF binding assay.
t Specific binding of TNF is given as a percent of specific binding
obtained at time 0 for buffer-treated cells, which averaged 7,626 ±
1,407 cpm/100 pg protein. Results are means ± SE of the number
of experiments in parentheses .
added to PMN for 90 min at 16°C before the binding assay
(not shown).
Selectivity ofLoss ofTNER Expression.
￿
Treatment ofPMN
with FMLP under conditions that led to almost complete
inhibition of binding of 1251--TNF did not affect the binding
of another cytokine (1251-IFN-y) nor the binding of mAbs
directed against HLA-A,B,C (Table 3) or a surface antigen
of 157 kD (30) (not shown). Under the same conditions,
cell surface expression of CD18 increased two- to threefold
(Table 3). Thus, the decrease in TNF-R induced by FMLP
was relatively selective.
Decreased Binding ofTNF Resultsfrom Loss ofTNF-R.
￿
The
rapid decrease of TNF binding induced by PMN activators
could be due to a conformational change of the receptor,
resulting in decreased affinity for its ligand, or to a loss of
receptors from thecell surface. To distinguish between these
possibilities, buffer- or FMLRtreated PMN were reactedwith
increasing concentrations of 1251-TNF and the specific bind-
ing values were analyzed according to Scatchard (35). Fig.
2 shows that FMLP reduced the total receptor number per
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￿
Efect of FMLP on Expression of TNF-R, IFN-y-R HLA, and CD18 Antigens on PMN
Figure 2.
￿
Equilibrium binding and Scatchard analysis of 1251TNF
binding to PMN incubated at 37°C for 15 min with 10-8 M FMLP
(/), 3 x 10-9 M FMLP (A), or buffer alone ("), as described in
Materials and Methods. (Inset) Scatchard analysis of specific binding
using the LIGAND program (36). The results are means of
duplicates.
cell from 1533 ± 132 for buffer-treated cells to 139 ± 54
and 629 ± 92 for cells incubated 15 min at 37°C with 10 -8
M or 3 x 10 -9 M FMLP, respectively, without any change
in affinity (Kd of 0.4 ± 0.16 nM for both buffer- and
FMLP-treated PMN). Results were similar afterexposure of
PMN to C5a, PMA, or A23187 at incompletely modulating
concentrations (Table 4) .
Independent evidence that TNF-Rwere lost from the cell
surface of activated PMN was provided by reacting FMLP-
andbuffer-treated PMNwith mAbs against TNF-R, followed
by 1251-F(ab')2 anti-mouse IgG. As shown in Table 5, incu-
bation with FMLP led to a decrease in binding of anti-
Specific binding (cpm/100 p.g of protein)#
PMN were incubated for 15 min at 37°C with either buffer alone or 10 -e M FMLP before binding assays for cytokines or mAbs as
described in Methods.
t Mean ± SE for triplicates.
S Percent of specific binding to cells treated with buffer alone.
Shedding of Tumor Necrosis Factor Receptors by Neutrophils
Time after
pulsing'
min
after
Buffer
exposure to:
FMLP
0 100 (5) 22 ± 4 (5)
45 100 ± 15 (5) 39 ± 5 (5)
120 84 ± 6 (3) 39 ± 11 (3)
Treatment" TNF IFN-y mAb anti-HLA-A,B,C mAb anti-CD18
None
FMLP
3,660 ± 306
896 ± 273
5,902 ± 539
6,606 ± 664
55,252
54,749 ±
± 4,228
10,400
35,290 ± 4,600
78,502 ± 5,280Table 4.
￿
Scatchard Analysis of TNF Binding by PMN Treated
with CSa, PMA, or A23187
Table 5.
￿
Effect of FMLP on Binding of TNF and
Anti-TNF-R mAbs to PMN
Specific binding#
Treatment"
￿
TNF
￿
anti-TNF-R mAbS
Control
￿
8,898 ± 818
￿
2,901 ± 382
" Parameters obtained by Scatchard analysis of specific binding by using
the LIGAND program (36). Means ± SD from the number of
independent experiments in parentheses.
0 PMN were treated for 45 min (t) or 10 min (S) at 37°C with the
indicated reagents before the binding assay. Stimuli were used at
lower concentrations than in Table 1 in order to induce incomplete
modulation of TNF binding sites and permit estimation of Kd and
sites/cell.
TNF-R mAbs similar in extent to the decrease in binding
of TNF.
Mechanism ofLoss of TNF-R.
￿
TNF binding sites could
disappearfrom the cell surfaceby internalizationor shedding.
To test for a role of endocytosis, PMN were pretreated with
themicrofilament-disrupting agent cytochalasin B (10 Ag/ml)
for 30 min at 37°C before adding FMLP. As shown in Fig.
3, cytochalasin Bdidnot prevent thedecrease in TNF binding
induced by FMLP. On the contrary, cytochalasin B syner-
gized with FMLP to augment loss of TNF-R.
To examine the possibility that activatedPMN might shed
TNF-R, we tested cell-free supernatants of stimulated PMN
for soluble TNF-R in a radioreceptor assay. PMN were in-
cubated for 10 min at 37°C with FMLP or buffer alone. The
cell-free incubation media were collected and their ability to
compete with 125I--TNF for itsbinding to fresh cells was ana-
lyzed at 4°C, a condition in which the indicator cells could
FMLP
￿
983 f 352 (11)11
￿
680 ± 263 (23)
" PMN were incubated for 10 min at 37°C with either buffer alone
or 10-7M FMLP and assayed for binding of TNF or mAbs as
described in Materials and Methods.
t Specific binding is given in cpm per 100 ug protein (means ± SD
for triplicates).
S mAbs Utr-1, Htr-5, and Htr-9 at 8 ug/ml each.
II Percent of specific binding to buffer-treated cells.
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Figure 3.
￿
Effect of cytochalasin B on FMLP-induced decrease in
TNF binding to PMN. PMN were incubated for 30 min at 37°C
with (O) or without (") 10 kg/ml cytochalasin B before adding the
indicated concentrations of FMLP for 15 min at 37°C. Binding of
1251--TNF was then assayed at 4°C. Results are means ± SE of
triplicates.
not respond to FMLP. As a control, FMLP was added to
supernatants of buffer-treated PMN during thebinding assay
at 4°C. Fig. 4 shows that supernatants from FMLP-stimulated
PMN inhibited 1251TNF binding to fresh PMN and mouse
macrophages, while supernatants from buffer-treated neutro-
phils had no effect.
100
80
60
40
20
0
FMLP concentration (M)
PMN
￿
Mouse M41
Figure 4.
￿
Competition for TNF binding to human PMN and
mouse macrophages (MO) by conditioned media from PMN treated
with FMLP (dashed bars) or buffer (open ban). PMN were incubated
with 10-6M FMLP or with buffer alone for 10 min at 37°C, and
cell-free supernatants were used as the medium in which to measure
125ITNF binding to untreated cells. Results are means ± SE of three
independent experiments and are expressed as a percent of specific
binding obtained in the absence of conditioned medium from PMN,
which averaged 1,897 ± 112 on PMN and 1,083 ± 185 on macro-
phages.
Treatment
Control
Kd (nM)"
nM
0.43 ± 0.16 2,122
Sites/cell"
± 545 (3)
Percent
of control
0
0
v
E a U
w U
C5a (10 nM)t 0.36 ± 0.07 710 ± 42 (2) 33 .
m
A23187 (1 AM)S 0.35 ± 0.03 1,512 ± 461 (2) 71 a
PMA (1 ng/ml)S 0.56 871 41To determine whether the moieties that blocked 1251-TNF
binding were related to TNF-R, we used antiTNF-RmAbs
Htr-5, Htr-9, and Utr-1, and chose murine macrophages as
indicator cells in the competition assay. The specificity of these
mAbs for the human as opposed to the mouse TNF-R was
shown by their ability to block completely the binding of
1251TNF to human PMN while inhibiting binding to mouse
macrophages by only 10-20% (Fig. 5 A) . Preincubation of
cell-free supernatants from FMLP-stimulated PMN with a
mixture of these mAbs (5 14g/ml each) totally reversed their
inhibitory effect on 1251-TNF binding to mouse macrophages
(Fig. 5 B) .
To test if TNF-R released from stimulated PMN were
soluble rather than associated with membrane fragments, su-
pernatants ofPMN treated withFMLP were ultracentrifuged
(100,000 g, 1 h, 4°C) or passed through a 0.22-jAm filter
(Millipore Corp ., Danvers, MA) . Neither procedure dimin-
ished the ability of the conditioned media to block 1251-TNF
binding to cells (data not shown) . Microscopic examination
ofboth FMLP- and buffer-treated PMN revealed monodisperse
cells with >95% viability by trypan blue exclusion, indicating
that the generation of soluble TNF-R from PMN was not
a consequence of cell death .
Characterization ofSoluble TNF-R by Ligand Blotting.
￿
Su-
pernatants from buffer- or FMLP-treatedPMN were subjected
to SDS-PAGE, transferred to nitrocellulose membranes and
probed with 1251TNF. Two 1251TNF binding proteins were
identified in the supernatants ofFMLP-stimulated PMN (Fig.
6 A) : a major species of ti95 kD and a N28-kD molecule
which appeared as a diffuse, less intense band . In the pres-
ence of a 200-fold excess of unlabeled TNF, binding of 1251_
TNF to the higher-Mr band was unaffected . The identity of
Figure 5 .
￿
Presence of TNF-R in conditioned medium of FMLP-
stimulated PMN . (A) Species specificity of inhibition of binding of
TNF by antiTNF-R mAbs. Human PMN or mouse macrophages
were incubated with either buffer alone (dashed bars) or mAbs Htr-5,
Htr-9, and Utr-1, 5 jig/ml each (filled bars), for 30 min at 4 °C, and
then assayed for 1251-TNF binding. Results are means ± SE of three
independent experiments. (B) Effect of antiTNF-R mAbs on inhibi-
tion of TNF binding to mouse macrophages by conditioned medium
from FMLP-stimulated PMN . Medium alone or cell-free supernatants
ofPMN treated with FMLP were incubated for 30 min at 4°C with
1251-TNF in the absence (open ban) or presence (filled bars) of the same
anti-TNF-R mAbs used in A, then added to mouse macrophages for
the binding assay. Results are means ± SE of triplicates .
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Figure 6.
￿
Ligand blot anal-
ysis of soluble TNF binding
proteins released by PMN.
Cell-free supernatants of PMN
stimulated with 10 -6 M FMLP
(lanes A and B) or buffer alone
(lane C) for 10 min at 37°C
were fractionated by 5-15%
SDS-PAGE under nonreducing
conditions, electrophoretically
transferred to nitrocellulose
membranes and blotted with
1251TNF in the absence (lanes
A and C) or presence (lane B)
of a 200-fold excess of unla-
beled TNF. Supernatants from
37 x 106 PMN were applied
per lane. Positions of prestained
M markers are indicated .
the ti95-kD protein that binds TNF nonspecifically is un-
known . In contrast, unlabeled TNF completely eliminated
binding of 1251TNF to the N28-kD protein (Fig . 6 B) .
However, no 1251TNF-binding proteins were detected in
ligand blots of supernatants from PMN that were not ex-
posed to FMLP (Fig. 6 C), even when autoradiography was
prolonged from 3 d (Fig . 6) to 3 wk (not shown) . Thus,
FMLP triggered PMN to release a soluble N28-kD protein
that bound TNF specifically .
Effect ofProtease Inhibitors.
￿
To test if proteolytic cleavage
were responsible for shedding ofTNF-R, PMN were stimu-
lated with FMLP in the presence or absence of inhibitors of
serine or thiol proteases . The decrease in 1251-TNF binding
to PMN induced by FMLP could not be prevented by addi-
tion of diisopropylfluorophosphate (DFP), trypsin inhibitor,
PMSF, leupeptin, aprotinin, or pepstatin (Table 6) .
Discussion
Downregulation of cell surface receptors is one means by
which cells control their responses to agonists . At least two
mechanisms serve to decrease the number ofTNF-R on var-
ious cells : internalization induced by homologous (27, 37,
38) or heterologous ligands (25, 26), and reduced rates of
TNF-R synthesis and/or translocation to the plasma mem-
brane (28) . Neither of these mechanisms has been detected
in PMN (25, 28) . In contrast, PMN appear to use a third
mechanism, shedding, to decrease rapidly the number of
TNF-R on their surface . Along with FcRIII (CD16) (39)
and the MEL14 selectin (40), TNF-R is the third plasma
membrane receptor that PMN areknown to shed upon acti-
vation .
Activators of PMN function that induced a decrease in
TNF-R included physiologic peptides (FMLP) and polypep-
tides (C5a, CSF-GM) ofbacterial orhuman origin, and phar-
macologic agents that activate protein kinase C (PMA,
A23187) . The decrease in TNF-R expression induced by all
these agents was rapid, and required cell metabolism, judging
by its temperature dependence. Shedding seemed to account
for at least part of the decreased expression of TNF-R, in
Factor Receptors by NeutrophilsTable 6.
￿
Effect ofProtease Inhibitors on FMLP-induced
Decrease in TNF-R
Protease inhibitor'
None
DFP (2.5 mM)
Trypsin inhibitor (1 mg/ml)
PMSF (0.5 mM) + leupeptin
(20 lAg/ml) + aprotinin (10 Wg/ml)
+ pepstatin (10 ug/ml)
TNF binding
(percent of control)$
11 ± 5
8 ± 4
12 ± 3
9 ± 3
' PMN were incubated for 15 min at 37'C with 10 -7 M FMLP
alone or in the presence of the indicated protease inhibitors before
the binding assay for TNF.
t Specific binding of TNF is given as a percent of specific binding
seen with cells treated with buffer alone, which averaged 5,008 ±
1,299 cpm/100 ttg protein. Results are means ± SD for triplicates.
that a loss of TNF-R binding sites (as estimated by Scatchard
analysis ofTNF binding, andby binding of anti-TNF-R mAbs)
was coincident with the appearance in the medium of soluble
molecules capable of binding both TNF and anti-TNF-R
mAbs. However, we could not quantitate soluble TNF-R,
and thus couldnot establish whether shedding accounted com-
pletely for the disappearance of TNF-R from the PMN sur-
face. It is possible that only some plasma membrane TNF-R
were shed; others may have been lost by internalization or
degradation. By whatever mechanism(s), the loss of TNF
binding sites often appeared to reach 100%.
Shedding of many plasma membrane receptors from cells
other than PMN has been described. Examples are the antigen-
binding molecules, MHC class I (41) and class 11 (42); the
adhesion molecule CD8 (43); and receptors for IgE (44), IIr2
(45), and insulin (46). The biochemical processes involved
are not well understood. In some instances, release of plasma
membrane vesicles is involved (41, 42) . This probably did
not account for shedding of TNF-R from PMN, since the
inhibitor of TNF binding in supernatants of activated PMN
was not sedimented by ultracentrifugation. Perhaps selective
proteolytic cleavage (45) releases TNF-R, while preserving
its ability to bind both TNF and anti TNF-R mAbs. If so,
then the role of PMN activators may be to promote exocy-
tosis of lysosomal proteases. However, we could not prevent
FMLP-induced loss of TNF-R with DFP, PMSF, soybean
trypsin inhibitor, leupeptin, and pepstatin. This militates
against a role for serine or thiol proteases, but leaves open
the possibility that a protease insensitive to these inhibitors
may be involved. Proteins anchored to membranes via glycosyl-
phosphatidylinositol can be shed after cleavage by phospholi-
pases (47). Such a mechanism may underlie the FMLRinduced
shedding of FcRIII (39). However, we were able to affect
the expression ofTNF-R on PMN with phosphatidylinositol-
specific phospholipase C (data not shown). We are only likely
to understand the mechanism of shedding of PMN TNF-R
afterboth its membrane and soluble forms have been purified.
Soluble TNF-binding proteins of 27 to 50 kD have been
isolated from the urine ofnormal (48) and febrile individuals
(49) and the sera of patients undergoing hemodialysis (50).
At least two of these proteins share immunological reactivity
with TNF-R of myeloid and epithelial cell lines (48) . The
findings presented here raise the possibility that some TNF-
binding proteins in body fluids may consist ofor derive from
TNF-R shed by PMN. The apparent 28,000 Mr of TNF-R
shed by PMN is consistent with this possibility.
At first glance, the observations made here in vitro might
appear to preclude the possibility that PMN can respond to
TNF in vivo, where multiple stimuli, including C5a and for-
mylated peptides of bacterial .(51) and/or mitochondrial (52)
origin, are likely to be present during infection or tissue in-
jury. However, consideration ofthis issue must take into ac-
count the rapidity with which the binding of TNF to its
receptor commits PMN to subsequent responses (Nathan,
C., unpublished observations), the retention of a substantial
number of TNF-R after exposure to C5a, and the sequence
in which PMN may encounter various stimuli as they move
from the circulation into tissues. Another key variable is
whether the PMN are in suspension, as in the present study,
or have made contact with biological surfaces before being
stimulated (Porteu, F., and C. Nathan, preliminary obser-
vations).
TNF is a major mediator of host responses to endotoxin
(4). Responses ofPMN to TNF may contribute to the patho-
genesis of septic shock and respiratory distress syndromes.
Downregulation of TNF-R on PMN that first encounter an-
other agonist in the circulation may represent an important
mechanism for protecting the host against deleterious effects
of TNF. At the same time, soluble TNF-R released by acti-
vated PMN might serve an immunoregulatory role by inter-
fering with the binding of TNF to other cells. Administra-
tion of soluble, recombinant, human TNF-R might protect
people against the consequences of excessive production of
TNF, without the antitherapeutic immune response expected
to follow the administration ofmAbs against TNF or TNF-R.
It is also possible that a soluble form ofTNF-Rhas cytokine-
like actions of its own, just as soluble FcERII mimics 1172
(53). If so, a cell surface receptor for soluble TNF-R could
be the 26-kD form of TNF present on the plasma membranes
of monocytes (54) and activated T cells (55). According to
this view, not only could mononuclear cells signal PMN (9),
but PMN could signal mononuclear cells in the regulation
of inflammatory responses.
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